The vaxelis market research report is one of a series of new reports that provides vaxelis market statistics, including the vaxelis industry's global market size, regional shares, competitors with a vaxelis market share, detailed vaxelis market segments, market trends and opportunities, and any further data you may need to thrive in the vaxelis industry. This vaxelis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to rising incidences of vaccine-preventable diseases, rising prevalence of infectious diseases, rising consumer trust in vaccination, rising demand for cost-effective vaccines, rising birth rates in developing regions, and increasing immunization coverage initiatives. Major trends in the forecast period include advancements in combination vaccine technology, advancements in vaccine production, advancements in cold chain infrastructure, innovation in vaccine formulation, and integration of digital health platforms.
The growth of the pediatric population is expected to significantly boost the demand for the Vaxelis vaccine in the future. This increase is largely driven by advancements in healthcare, improved nutrition, better maternal care, a reduction in infant mortality rates, and heightened awareness of child health and vaccination initiatives. Vaxelis, which offers protection against six serious diseases in a single vaccine, simplifies immunization for children and reduces the burden of multiple injections. For example, in December 2024, Child Stats, a U.S.-based federal forum for child and family statistics, reported that in 2022, the U.S. had 72.5 million children, with projections indicating this number will grow to 78.2 million by 2050. This expanding pediatric population is a key factor driving the demand for Vaxelis.
The growing prevalence of hepatitis B is also expected to fuel the growth of the Vaxelis market in the coming years. Hepatitis B is a viral infection that affects the liver and can result in both acute and chronic diseases such as cirrhosis and liver cancer. The rising number of hepatitis B cases can be attributed to factors such as inadequate vaccination coverage, weak healthcare infrastructure, high-risk behaviors such as needle sharing, and a lack of public awareness about prevention. Vaxelis helps combat this issue by providing immunity against hepatitis B, incorporating the hepatitis B surface antigen into its vaccine formulation to prevent infection and its complications. According to a report by the European Centre for Disease Prevention and Control (ECDC) in April 2024, around 257 million people globally were living with hepatitis B in 2022, with 1.5 million new cases reported annually. This increasing prevalence of hepatitis B is driving the demand for Vaxelis.
Rising healthcare expenditure is expected to contribute to the growth of the Vaxelis market as well. Healthcare expenditure refers to the financial resources allocated by governments, private insurers, and individuals toward improving and expanding healthcare services. This increase in spending plays a critical role in supporting vaccination programs, enhancing access to immunization, and funding public health campaigns that promote vaccine awareness and distribution. For instance, in May 2023, the Office for National Statistics reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a mere 0.9% growth in the previous year. The UK's healthcare expenditure in 2023 amounted to approximately $317.63 billion (£292 billion). This rise in healthcare spending is expected to drive the growth of the Vaxelis market by improving access to vaccines and encouraging wider adoption.
The key players in the vaxelis market are Merck & Co. Inc., and Sanofi S.A.
North America was the largest region in the vaxelis market in 2024. The regions covered in vaxelis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaxelis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vaxelis is a six-in-one vaccine designed to protect against diphtheria, tetanus, whooping cough, polio, Haemophilus influenzae type B infections, and hepatitis B. It is primarily administered to infants and children as part of routine vaccination programs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Vaxelis include pertussis, diphtheria, and tetanus. Pertussis, also known as whooping cough, is a highly contagious respiratory infection caused by Bordetella pertussis, characterized by severe coughing fits that can make breathing difficult. Vaxelis helps protect against pertussis by stimulating the immune system to prevent infection and reduce the severity of symptoms in children. The vaccine is distributed through various channels, including hospitals, retail pharmacies, and government supplies, and is used by a wide range of end users such as hospitals, clinics, ambulatory care settings, and home care providers.
The vaxelis market consists of sales of active ingredients and antigens, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising incidences of vaccine-preventable diseases, rising prevalence of infectious diseases, rising consumer trust in vaccination, rising demand for cost-effective vaccines, rising birth rates in developing regions, and increasing immunization coverage initiatives. Major trends in the forecast period include advancements in combination vaccine technology, advancements in vaccine production, advancements in cold chain infrastructure, innovation in vaccine formulation, and integration of digital health platforms.
The growth of the pediatric population is expected to significantly boost the demand for the Vaxelis vaccine in the future. This increase is largely driven by advancements in healthcare, improved nutrition, better maternal care, a reduction in infant mortality rates, and heightened awareness of child health and vaccination initiatives. Vaxelis, which offers protection against six serious diseases in a single vaccine, simplifies immunization for children and reduces the burden of multiple injections. For example, in December 2024, Child Stats, a U.S.-based federal forum for child and family statistics, reported that in 2022, the U.S. had 72.5 million children, with projections indicating this number will grow to 78.2 million by 2050. This expanding pediatric population is a key factor driving the demand for Vaxelis.
The growing prevalence of hepatitis B is also expected to fuel the growth of the Vaxelis market in the coming years. Hepatitis B is a viral infection that affects the liver and can result in both acute and chronic diseases such as cirrhosis and liver cancer. The rising number of hepatitis B cases can be attributed to factors such as inadequate vaccination coverage, weak healthcare infrastructure, high-risk behaviors such as needle sharing, and a lack of public awareness about prevention. Vaxelis helps combat this issue by providing immunity against hepatitis B, incorporating the hepatitis B surface antigen into its vaccine formulation to prevent infection and its complications. According to a report by the European Centre for Disease Prevention and Control (ECDC) in April 2024, around 257 million people globally were living with hepatitis B in 2022, with 1.5 million new cases reported annually. This increasing prevalence of hepatitis B is driving the demand for Vaxelis.
Rising healthcare expenditure is expected to contribute to the growth of the Vaxelis market as well. Healthcare expenditure refers to the financial resources allocated by governments, private insurers, and individuals toward improving and expanding healthcare services. This increase in spending plays a critical role in supporting vaccination programs, enhancing access to immunization, and funding public health campaigns that promote vaccine awareness and distribution. For instance, in May 2023, the Office for National Statistics reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a mere 0.9% growth in the previous year. The UK's healthcare expenditure in 2023 amounted to approximately $317.63 billion (£292 billion). This rise in healthcare spending is expected to drive the growth of the Vaxelis market by improving access to vaccines and encouraging wider adoption.
The key players in the vaxelis market are Merck & Co. Inc., and Sanofi S.A.
North America was the largest region in the vaxelis market in 2024. The regions covered in vaxelis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaxelis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vaxelis is a six-in-one vaccine designed to protect against diphtheria, tetanus, whooping cough, polio, Haemophilus influenzae type B infections, and hepatitis B. It is primarily administered to infants and children as part of routine vaccination programs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Vaxelis include pertussis, diphtheria, and tetanus. Pertussis, also known as whooping cough, is a highly contagious respiratory infection caused by Bordetella pertussis, characterized by severe coughing fits that can make breathing difficult. Vaxelis helps protect against pertussis by stimulating the immune system to prevent infection and reduce the severity of symptoms in children. The vaccine is distributed through various channels, including hospitals, retail pharmacies, and government supplies, and is used by a wide range of end users such as hospitals, clinics, ambulatory care settings, and home care providers.
The vaxelis market consists of sales of active ingredients and antigens, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vaxelis Market Characteristics4. Vaxelis Market Trends And Strategies5. Vaxelis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vaxelis Pricing Analysis & Forecasts30. Global Vaxelis Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vaxelis Market32. Recent Developments In The Vaxelis Market
3. Vaxelis Market Biologic Drug Characteristics
6. Global Vaxelis Growth Analysis And Strategic Analysis Framework
8. Vaxelis Market Segmentation
9. Global Vaxelis Epidemiology Of Clinical Indications
10. Vaxelis Market Regional And Country Analysis
11. Asia-Pacific Vaxelis Market
12. China Vaxelis Market
13. India Vaxelis Market
14. Japan Vaxelis Market
15. Australia Vaxelis Market
16. South Korea Vaxelis Market
17. Western Europe Vaxelis Market
18. UK Vaxelis Market
19. Germany Vaxelis Market
20. France Vaxelis Market
21. Eastern Europe Vaxelis Market
22. North America Vaxelis Market
23. USA Vaxelis Market
24. Canada Vaxelis Market
25. South America Vaxelis Market
26. Middle East Vaxelis Market
27. Africa Vaxelis Market
28. Vaxelis Market Competitive Landscape And Company Profiles
29. Global Vaxelis Market Pipeline Analysis
33. Vaxelis Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vaxelis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vaxelis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vaxelis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaxelis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Pertussis; Diphtheria; Tetanus2) By Distribution Channel: Hospitals; Retail Pharmacies; Government Supplies
3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: Merck & Co. Inc.; Sanofi S.A.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
- Sanofi S.A.
